This is a Validated Antibody Database (VAD) review about human MSH2, based on 60 published articles (read how Labome selects the articles), using MSH2 antibody in all methods. It is aimed to help Labome visitors find the most suited MSH2 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
MSH2 synonym: COCA1; FCC1; HNPCC; HNPCC1; LCFS2; hMSH2

Knockout validation
Invitrogen
mouse monoclonal (FE11)
  • western blot knockout validation; mouse; loading ...; fig s2a
Invitrogen MSH2 antibody (Invitrogen, FE11) was used in western blot knockout validation on mouse samples (fig s2a). Science (2019) ncbi
Abcam
domestic rabbit monoclonal (SP46)
  • western blot knockout validation; dogs; 1:50; fig 6
Abcam MSH2 antibody (Abcam, SP46) was used in western blot knockout validation on dogs samples at 1:50 (fig 6). J Vet Intern Med (2022) ncbi
Abcam
domestic rabbit polyclonal
  • western blot knockout validation; mouse; 1:10,000; fig 4
Abcam MSH2 antibody (Abcam, ab70270) was used in western blot knockout validation on mouse samples at 1:10,000 (fig 4). PLoS Genet (2016) ncbi
Invitrogen
mouse monoclonal (FE11)
  • western blot; human; loading ...; fig 1s1c
Invitrogen MSH2 antibody (Thermo Fisher, 33-7900) was used in western blot on human samples (fig 1s1c). elife (2019) ncbi
mouse monoclonal (FE11)
  • western blot knockout validation; mouse; loading ...; fig s2a
Invitrogen MSH2 antibody (Invitrogen, FE11) was used in western blot knockout validation on mouse samples (fig s2a). Science (2019) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; loading ...; tbl 2
In order to determine the prognostic impact of parameters in peritoneal carcinomatosis from colorectal cancer, Invitrogen MSH2 antibody (Invitrogen, FE11) was used in immunohistochemistry - paraffin section on human samples (tbl 2). Am J Surg (2017) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:50; fig s1
In order to utilize ovarian cancer xenograft models to study dynamic modulation of phosphoprotein expression, Invitrogen MSH2 antibody (Invitrogen, 33-7900) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig s1). BMC Cancer (2016) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:200
In order to assess how proportional balance of tumor associated macrophages and tumor infiltrating lymphocytes in microsatellite-unstable gastric carcinoma is a prognostic indicator of M2 macrophages, Invitrogen MSH2 antibody (Invitrogen, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:200. PLoS ONE (2015) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human
In order to elucidate the clinicopathologic characteristics of hereditary nonpolyposis colorectal cancer patients who had both endometrial and colorectal cancers, Invitrogen MSH2 antibody (Life Technologies, FE11) was used in immunohistochemistry - paraffin section on human samples . Obstet Gynecol Sci (2015) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry; human; 1:100; loading ...
In order to assess the detection of the BRAF mutation by immunohistochemistry on tissue microarray, Invitrogen MSH2 antibody (Invitrogen, FE11) was used in immunohistochemistry on human samples at 1:100. Appl Immunohistochem Mol Morphol (2016) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:200
In order to determine the association of microsatellite instability with mismatch repair proteins in epithelial cancer samples, Invitrogen MSH2 antibody (Zymed/Invitrogen, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:200. Genet Test Mol Biomarkers (2014) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry; human; 1:100; fig 1
In order to identify and characterize BRAF mutation from patients with metanephric adenomas, Invitrogen MSH2 antibody (Invitrogen, FE11) was used in immunohistochemistry on human samples at 1:100 (fig 1). Cancer Genet (2013) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; fig 2
In order to report the first case of filiform polyposis associated with adenomas developed on filiform polyps and invasive colonic adenocarcinoma in a patient without history of inflammatory bowel disease, Invitrogen MSH2 antibody (Invitrogen, FE11) was used in immunohistochemistry - paraffin section on human samples (fig 2). Pathol Res Pract (2014) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry; human; 1:250; tbl 1
In order to study the elevated hMLH1 expression observed in EGFR-mutated non-small cell lung cancer, Invitrogen MSH2 antibody (Invitrogen, clone FE11) was used in immunohistochemistry on human samples at 1:250 (tbl 1). PLoS ONE (2013) ncbi
mouse monoclonal (FE11)
  • western blot; human; fig 7
In order to assess the effects of fermentation products produced by the human gut flora on human adenocarcinoma colon cancer cells, Invitrogen MSH2 antibody (Invitrogen, 33-7900) was used in western blot on human samples (fig 7). J Agric Food Chem (2012) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 2
In order to examine mismatch repair protein expression in epithelial ovarian cancer samples, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 2). Anticancer Res (2012) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; fig 3
In order to elucidate the pathogenesis of diffuse large B-cell lymphoma, Invitrogen MSH2 antibody (ZYMED, FE11) was used in immunohistochemistry - paraffin section on human samples (fig 3). Leuk Lymphoma (2013) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; fig 3
In order to determine the roles of p53 and hMSH2 proteins in oral squamous cell carcinoma and oral dysplastic lesions, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples (fig 3). Oral Oncol (2012) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human
In order to examine patients with renal medullary carcinoma with and without sickle cell anemia, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples . Hum Pathol (2011) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:400; fig 4
In order to elucidate how synthetic sickness/lethality affects cancer cells, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 4). Cancer Cell (2010) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human
In order to measure the frequency of mismatch repair deficiencies in women diagnosed with endometrial cancer who are at-risk for Lynch syndrome, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples . Fam Cancer (2010) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:100
In order to discuss biomarkers for insulinomas, Invitrogen MSH2 antibody (Zymed Laboratories, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:100. J Clin Endocrinol Metab (2009) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:200; fig 2
In order to assess the relationship between clinicopathological features and expression of hMLH1 and hMSH2 proteins in pleomorphic adenoma of minor salivary glands, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 2). Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:150
In order to correlate microstellite instability and other clinicopathologic markers with survival of patients with high grade endometrial carcinoma, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:150. Gynecol Oncol (2009) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:200
In order to discuss the use of microarrays to study ovarian cancer, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:200. Cancer Epidemiol Biomarkers Prev (2009) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; fig 1
In order to determine the expression of Bcl-2, hMLH1, and hMSH2 in patients with advanced colorectal cancer and correlate their expression with therapeutic response and disease outcome, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples (fig 1). Oncol Rep (2008) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:140
In order to detect expression of MMR gene products hMSH2 and hMSH6 in urothelial carcinoma of the bladder, Invitrogen MSH2 antibody (Zymed Laboratories, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:140. APMIS (2008) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:250; fig 1
In order to quantify expression levels of mismatch repair proteins hMSH2, hMLH1, PCNA and Ki67 in the mucosae collected from the patients with gastric cancer, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:250 (fig 1). Oncol Rep (2008) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human
In order to identify the number of hereditary nonpolyposis colorectal cancer patients that exist among endometrial cancer patients, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples . Int J Cancer (2008) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:100
In order to evaluate thymidylate synthase and microsatellite instability in colorectal cancer, Invitrogen MSH2 antibody (Zymed Laboratories, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:100. Acta Oncol (2008) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:400; fig 1
In order to provide evidence that carcinosarcomas are clonal malignancies, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 1). Mod Pathol (2006) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human
In order to assess patients with pure squamous cell carcinoma of the uterine cervix for loss of heterozygosity and microsatellite instability, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples . Int J Gynecol Cancer (2006) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry; human; 1:100
In order to discuss the numbers of colorectal cancer cases based on Amsterdam I and II criteria, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry on human samples at 1:100. Fam Cancer (2005) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human
In order to compare alpha-methylacyl coenzyme A racemase expression in primary small intestinal adenocarcinomas and colorectal adenocarcinomas, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples . Am J Surg Pathol (2005) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human
In order to study the role of high thymidylate synthase expression in colorectal cancer with microsatellite instability, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples . Clin Cancer Res (2005) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry; human; 1:20
In order to determine the function of BRAF in ulcerative colitis-related colorectal carcinogenesis, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry on human samples at 1:20. Int J Cancer (2005) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:400
In order to identify the molecular profiles of patients with rectal cancers treated with neoadjuvant chemotherapy, radiotherapy, and surgery that correlate therapeutic responses, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:400. Anticancer Res (2004) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:400
In order to elucidate how crypt stem cells contribute to the development of colon cancer, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:400. Am J Pathol (2004) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:400; fig 4
In order to assess the number and types of malignancies in patients with endometrial carcinoma with and without microsatellite instability, Invitrogen MSH2 antibody (Zymed, FE11) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 4). Clin Cancer Res (2004) ncbi
Abcam
domestic rabbit monoclonal (SP46)
  • western blot knockout validation; dogs; 1:50; fig 6
Abcam MSH2 antibody (Abcam, SP46) was used in western blot knockout validation on dogs samples at 1:50 (fig 6). J Vet Intern Med (2022) ncbi
domestic rabbit monoclonal (EPR3943)
  • western blot; human; loading ...; fig s1
Abcam MSH2 antibody (Abcam, ab92473) was used in western blot on human samples (fig s1). Aging (Albany NY) (2021) ncbi
domestic rabbit polyclonal
  • western blot knockout validation; mouse; 1:10,000; fig 4
Abcam MSH2 antibody (Abcam, ab70270) was used in western blot knockout validation on mouse samples at 1:10,000 (fig 4). PLoS Genet (2016) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D24B5)
  • western blot; human; 1:1000; loading ...; fig 4b
  • western blot; mouse; 1:1000; loading ...; fig 3d
Cell Signaling Technology MSH2 antibody (Cell Signaling, 2017) was used in western blot on human samples at 1:1000 (fig 4b) and in western blot on mouse samples at 1:1000 (fig 3d). Adv Sci (Weinh) (2022) ncbi
domestic rabbit monoclonal (D24B5)
  • immunohistochemistry; mouse; 1:500; loading ...
Cell Signaling Technology MSH2 antibody (Cell Signaling Technology, 2017) was used in immunohistochemistry on mouse samples at 1:500. JCI Insight (2020) ncbi
mouse monoclonal (3A2)
  • reverse phase protein lysate microarray; human; loading ...; fig st6
In order to characterize the molecular identity of uterine carcinosarcomas., Cell Signaling Technology MSH2 antibody (CST, 2850) was used in reverse phase protein lysate microarray on human samples (fig st6). Cancer Cell (2017) ncbi
mouse monoclonal (3A2)
  • reverse phase protein lysate microarray; human; loading ...; fig 3a
In order to describe the features of 228 primary cervical cancers, Cell Signaling Technology MSH2 antibody (Cell Signaling, 2850) was used in reverse phase protein lysate microarray on human samples (fig 3a). Nature (2017) ncbi
domestic rabbit monoclonal (D24B5)
  • western blot; human; fig s3
Cell Signaling Technology MSH2 antibody (Signaling Technology, 2017) was used in western blot on human samples (fig s3). J Cell Mol Med (2016) ncbi
domestic rabbit monoclonal (D24B5)
  • western blot; human; 1:1000; fig 1g
In order to elucidate the function of TRIM29 in double stranded break repair, Cell Signaling Technology MSH2 antibody (Cell signalling, 2,017) was used in western blot on human samples at 1:1000 (fig 1g). Nat Commun (2015) ncbi
mouse monoclonal (3A2)
  • western blot; human; 1:1000; loading ...; fig 2a
Cell Signaling Technology MSH2 antibody (Cell signaling, 2850) was used in western blot on human samples at 1:1000 (fig 2a). Oncotarget (2016) ncbi
domestic rabbit monoclonal (D24B5)
  • immunohistochemistry - paraffin section; human; 1:200
  • western blot; human
In order to evaluate the effect of NVP-BEZ235 and MEK inhibitor ADZ4266 on murine mismatch repair deficient tumors, Cell Signaling Technology MSH2 antibody (Cell Signaling Technologies, 2017S) was used in immunohistochemistry - paraffin section on human samples at 1:200 and in western blot on human samples . PLoS ONE (2013) ncbi
Dako
mouse monoclonal (FE11)
  • immunocytochemistry; human; 1:50; loading ...; fig 2d
In order to determine the effect of chronic smoking on repair gene expression in the normal oral mucosa of chronic smokers and never smokers, Dako MSH2 antibody (DakoCorporation, FE11) was used in immunocytochemistry on human samples at 1:50 (fig 2d). Arch Oral Biol (2017) ncbi
mouse monoclonal (FE11)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; tbl 1
Dako MSH2 antibody (Dako, M3639) was used in immunohistochemistry - paraffin section on human samples at 1:50 (tbl 1). Br J Cancer (2016) ncbi
Cell Marque
mouse monoclonal (G219-1129)
  • immunohistochemistry; human; 1:700; loading ...; fig 1, 2a, 2b
Cell Marque MSH2 antibody (Cell Marque, G219?C1129) was used in immunohistochemistry on human samples at 1:700 (fig 1, 2a, 2b). Acta Neuropathol Commun (2020) ncbi
Leica Biosystems
monoclonal (25D12)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; tbl 1
Leica Biosystems MSH2 antibody (Novocastra, PA0057) was used in immunohistochemistry - paraffin section on human samples at 1:50 (tbl 1). ESMO Open (2022) ncbi
monoclonal (25D12)
  • immunohistochemistry - paraffin section; rat; 1:300; loading ...; fig s6b
In order to develop and characterize a rat model of glioma, Leica Biosystems MSH2 antibody (Leica Microsystems, PA0057) was used in immunohistochemistry - paraffin section on rat samples at 1:300 (fig s6b). PLoS ONE (2017) ncbi
monoclonal (25D12)
  • immunohistochemistry - paraffin section; human; 1:50
In order to use Romanian patients with gastric carcinomas and compare the demographic, clinical, and immunohistochemical aspects of each cancer, Leica Biosystems MSH2 antibody (Novocastra, 25D12) was used in immunohistochemistry - paraffin section on human samples at 1:50. APMIS (2015) ncbi
monoclonal (25D12)
  • immunohistochemistry; human; 1:100
In order to identify tissue origin of the granular cell tumor using immunohistochemistry, Leica Biosystems MSH2 antibody (Novocastra, 25D12) was used in immunohistochemistry on human samples at 1:100. Arch Dermatol Res (2015) ncbi
monoclonal (25D12)
  • immunohistochemistry - paraffin section; human; 1:100
Leica Biosystems MSH2 antibody (Novocastra Lab, 25D12) was used in immunohistochemistry - paraffin section on human samples at 1:100. PLoS ONE (2014) ncbi
BD Biosciences
mouse monoclonal (G219-1129)
  • other; human; loading ...; fig st1
In order to use size exclusion chromatography-microsphere-based affinity proteomics to study clinical samples obtained from pediatric acute leukemia patients, BD Biosciences MSH2 antibody (BD, G219-1129) was used in other on human samples (fig st1). Mol Cell Proteomics (2016) ncbi
mouse monoclonal (G219-1129)
  • western blot; human; 1:1000; fig 1
BD Biosciences MSH2 antibody (BD Biosciences, 556349) was used in western blot on human samples at 1:1000 (fig 1). Nucleic Acids Res (2016) ncbi
mouse monoclonal (G219-1129)
  • western blot; human
In order to explore DNA repair responses in human pluripotent stem cells, BD Biosciences MSH2 antibody (BD Biosciences, 556349) was used in western blot on human samples . J Biol Chem (2014) ncbi
mouse monoclonal (G219-1129)
  • immunohistochemistry - paraffin section; human; 1:20
In order to discuss the diagnosis of colorectal cancer and the need for genetic testing for Lynch Syndrome in young patients, BD Biosciences MSH2 antibody (Biosciences Company, 556349) was used in immunohistochemistry - paraffin section on human samples at 1:20. BMC Surg (2014) ncbi
mouse monoclonal (G219-1129)
  • immunohistochemistry - paraffin section; human; 1:100
BD Biosciences MSH2 antibody (BD Pharmingen, G219-1129) was used in immunohistochemistry - paraffin section on human samples at 1:100. BMC Gastroenterol (2013) ncbi
Articles Reviewed
  1. Inanaga S, Igase M, Sakai Y, Hagimori K, Sunahara H, Horikirizono H, et al. Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs. J Vet Intern Med. 2022;36:1760-1769 pubmed publisher
  2. Kumar D, Das M, Oberg A, Sahoo D, Wu P, Sauceda C, et al. Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma. Adv Sci (Weinh). 2022;9:e2105120 pubmed publisher
  3. Simbolo M, Centonze G, Ali G, Garzone G, Taormina S, Sabella G, et al. Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. ESMO Open. 2022;7:100308 pubmed publisher
  4. Zhou Z, Tan F, Pei Q, Li C, Zhou Y, Li Y, et al. lncRNA SNHG4 modulates colorectal cancer cell cycle and cell proliferation through regulating miR-590-3p/CDK1 axis. Aging (Albany NY). 2021;13:9838-9858 pubmed publisher
  5. Li H, Lu C, Zhang H, Hu Q, Zhang J, Cuevas I, et al. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight. 2020;5: pubmed publisher
  6. McCord M, Steffens A, Javier R, Kam K, McCortney K, Horbinski C. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas. Acta Neuropathol Commun. 2020;8:15 pubmed publisher
  7. Pech M, Fong L, Villalta J, Chan L, Kharbanda S, O Brien J, et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. elife. 2019;8: pubmed publisher
  8. Mandal R, Samstein R, Lee K, Havel J, Wang H, Krishna C, et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science. 2019;364:485-491 pubmed publisher
  9. Connolly N, Stokum J, Schneider C, Ozawa T, Xu S, Galisteo R, et al. Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer. PLoS ONE. 2017;12:e0174557 pubmed publisher
  10. Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed publisher
  11. . Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed publisher
  12. Massalou D, Benizri E, Chevallier A, Duranton Tanneur V, Pedeutour F, Benchimol D, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213:377-387 pubmed publisher
  13. Alves M, Carta C, de Barros P, Issa J, Nunes F, Almeida J. Repair genes expression profile of MLH1, MSH2 and ATM in the normal oral mucosa of chronic smokers. Arch Oral Biol. 2017;73:60-65 pubmed publisher
  14. Ah Koon L, Lesage D, Lemadre E, Souissi I, Fagard R, Varin Blank N, et al. Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells. J Cell Mol Med. 2016;20:1956-65 pubmed publisher
  15. Zhao X, Lokanga R, Allette K, Gazy I, Wu D, Usdin K. A MutS?-Dependent Contribution of MutS? to Repeat Expansions in Fragile X Premutation Mice?. PLoS Genet. 2016;12:e1006190 pubmed publisher
  16. Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed publisher
  17. Park J, Powell A, Roxburgh C, Horgan P, McMillan D, Edwards J. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer. 2016;114:562-70 pubmed publisher
  18. Kanderová V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, et al. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016;15:1246-61 pubmed publisher
  19. Kim K, Wen X, Yang H, Kim W, Kang G. Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma. PLoS ONE. 2015;10:e0144192 pubmed publisher
  20. Ortega Atienza S, Wong V, Deloughery Z, Luczak M, Zhitkovich A. ATM and KAT5 safeguard replicating chromatin against formaldehyde damage. Nucleic Acids Res. 2016;44:198-209 pubmed publisher
  21. Masuda Y, Takahashi H, Sato S, Tomomori Sato C, Saraf A, Washburn M, et al. TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin. Nat Commun. 2015;6:7299 pubmed publisher
  22. Maachani U, Tandle A, Shankavaram U, Kramp T, Camphausen K. Modulation of miR-21 signaling by MPS1 in human glioblastoma. Oncotarget. 2016;7:52912-52927 pubmed publisher
  23. Shin S, Yu E, Lee Y, Song Y, Seong M, Park S. Characteristics of hereditary nonpolyposis colorectal cancer patients with double primary cancers in endometrium and colorectum. Obstet Gynecol Sci. 2015;58:112-6 pubmed publisher
  24. Boulagnon C, Dudez O, Beaudoux O, Dalstein V, Kianmanesh R, Bouché O, et al. BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: An 86 Case Series. Appl Immunohistochem Mol Morphol. 2016;24:88-96 pubmed publisher
  25. Gurzu S, Kádár Z, Sugimura H, Bara T, Hălmaciu I, Jung I. Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity. APMIS. 2015;123:223-33 pubmed publisher
  26. Gurzu S, Ciortea D, Tamasi A, Golea M, Bodi A, Sahlean D, et al. The immunohistochemical profile of granular cell (Abrikossoff) tumor suggests an endomesenchymal origin. Arch Dermatol Res. 2015;307:151-7 pubmed publisher
  27. Lin B, Gupta D, Heinen C. Human pluripotent stem cells have a novel mismatch repair-dependent damage response. J Biol Chem. 2014;289:24314-24 pubmed publisher
  28. Koppensteiner R, Samartzis E, Noske A, von Teichman A, Dedes I, Gwerder M, et al. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS ONE. 2014;9:e100041 pubmed publisher
  29. Lee J, Cragun D, Thompson Z, Coppola D, Nicosia S, Akbari M, et al. Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer. Genet Test Mol Biomarkers. 2014;18:229-35 pubmed publisher
  30. Baiocchi G, Portolani N, Vermi W, Baronchelli C, Gheza F, Zogno C, et al. Lynch syndrome from a surgeon perspective: retrospective study of clinical impact of mismatch repair protein expression analysis in colorectal cancer patients less than 50 years old. BMC Surg. 2014;14:9 pubmed publisher
  31. Dadone B, Ambrosetti D, Carpentier X, Duranton Tanneur V, Burel Vandenbos F, Amiel J, et al. A renal metanephric adenoma showing both a 2p16e24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?. Cancer Genet. 2013;206:347-52 pubmed
  32. Boulagnon C, Jazeron J, Diaz Cives A, Ehrhard F, Bouche O, Diebold M. Filiform polyposis: A benign entity? Case report and literature review. Pathol Res Pract. 2014;210:189-93 pubmed publisher
  33. Li M, Zhang Q, Liu L, Lu W, Wei H, Li R, et al. Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations. PLoS ONE. 2013;8:e78500 pubmed publisher
  34. Kucherlapati M, Esfahani S, Habibollahi P, Wang J, Still E, Bronson R, et al. Genotype directed therapy in murine mismatch repair deficient tumors. PLoS ONE. 2013;8:e68817 pubmed publisher
  35. Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol. 2013;13:36 pubmed publisher
  36. Campos Vega R, García Gasca T, Guevara González R, Ramos Gomez M, Oomah B, Loarca Pina G. Human gut flora-fermented nondigestible fraction from cooked bean ( Phaseolus vulgaris L.) modifies protein expression associated with apoptosis, cell cycle arrest, and proliferation in human adenocarcinoma colon cancer cells. J Agric Food Chem. 2012;60:12443-50 pubmed publisher
  37. Coppola D, Nicosia S, Doty A, Sellers T, Lee J, Fulp J, et al. Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer. Anticancer Res. 2012;32:4963-9 pubmed
  38. Couronné L, Ruminy P, Waultier Rascalou A, Rainville V, Cornic M, Picquenot J, et al. Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:1079-86 pubmed publisher
  39. Helal T, Fadel M, El Thobbani A, El Sarhi A. Immunoexpression of p53 and hMSH2 in oral squamous cell carcinoma and oral dysplastic lesions in Yemen: relationship to oral risk habits and prognostic factors. Oral Oncol. 2012;48:120-4 pubmed publisher
  40. Gatalica Z, Lilleberg S, Monzon F, Koul M, Bridge J, Knezetic J, et al. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes. Hum Pathol. 2011;42:1979-88 pubmed publisher
  41. Martin S, McCabe N, Mullarkey M, Cummins R, Burgess D, Nakabeppu Y, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell. 2010;17:235-48 pubmed publisher
  42. Cossio S, Koehler Santos P, Pessini S, Mónego H, Edelweiss M, Meurer L, et al. Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil. Fam Cancer. 2010;9:131-9 pubmed publisher
  43. Mei M, Deng D, Liu T, Sang X, Lu X, Xiang H, et al. Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. J Clin Endocrinol Metab. 2009;94:3448-57 pubmed publisher
  44. Tobón Arroyave S, Flórez Moreno G, Jaramillo Cárdenas J, Arango Uribe J, Isaza Guzmán D, Rendón Henao J. Expression of hMLH1 and hMSH2 proteins in pleomorphic adenoma of minor salivary glands: relationship with clinical and histologic findings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108:227-36 pubmed publisher
  45. Arabi H, Guan H, Kumar S, Cote M, Bandyopadhyay S, Bryant C, et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol. 2009;113:153-8 pubmed publisher
  46. Permuth Wey J, Boulware D, Valkov N, Livingston S, Nicosia S, Lee J, et al. Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:28-34 pubmed publisher
  47. Bendardaf R, Lamlum H, Ristamaki R, Syrjanen K, Pyrhonen S. Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. Oncol Rep. 2008;20:999-1004 pubmed
  48. Mylona E, Zarogiannos A, Nomikos A, Giannopoulou I, Nikolaou I, Zervas A, et al. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder. APMIS. 2008;116:59-65 pubmed publisher
  49. Li M, Liu L, Wang Z, Wang L, Liu Z, Xu G, et al. Overexpression of hMSH2 and hMLH1 protein in certain gastric cancers and their surrounding mucosae. Oncol Rep. 2008;19:401-6 pubmed
  50. Yoon S, Ku J, Shin Y, Kim K, Choi J, Jang E, et al. Hereditary nonpolyposis colorectal cancer in endometrial cancer patients. Int J Cancer. 2008;122:1077-81 pubmed
  51. Bendardaf R, Lamlum H, Ristamaki R, Korkeila E, Syrjanen K, Pyrhonen S. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases. Acta Oncol. 2008;47:1046-53 pubmed
  52. Taylor N, Zighelboim I, Huettner P, Powell M, Gibb R, Rader J, et al. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol. 2006;19:1333-8 pubmed
  53. Edelmann J, Richter K, Hanel C, Hering S, Horn L. X chromosomal and autosomal loss of heterozygosity and microsatellite instability in human cervical carcinoma. Int J Gynecol Cancer. 2006;16:1248-53 pubmed
  54. Kerber R, Neklason D, Samowitz W, Burt R. Frequency of familial colon cancer and hereditary nonpolyposis colorectal cancer (Lynch syndrome) in a large population database. Fam Cancer. 2005;4:239-44 pubmed
  55. Chen Z, Ritter J, Wang H. Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol. 2005;29:890-6 pubmed
  56. Ricciardiello L, Ceccarelli C, Angiolini G, Pariali M, Chieco P, Paterini P, et al. High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin Cancer Res. 2005;11:4234-40 pubmed
  57. Aust D, Haase M, Dobryden L, Markwarth A, Löhrs U, Wittekind C, et al. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. Int J Cancer. 2005;115:673-7 pubmed
  58. Charara M, Edmonston T, Burkholder S, Walters R, Anne P, Mitchell E, et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res. 2004;24:3161-7 pubmed
  59. Boman B, Walters R, Fields J, Kovatich A, Zhang T, Isenberg G, et al. Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population. Am J Pathol. 2004;165:1489-98 pubmed
  60. Buttin B, Powell M, Mutch D, Rader J, Herzog T, Gibb R, et al. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res. 2004;10:481-90 pubmed